All In Biotech

Drug Trial Radar · NCT01999218

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Last checked: Nov 20, 2026Latest source record: Apr 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,326 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,326

Actual

Start

Dec 16, 2013

Primary completion

Apr 18, 2017

Study completion Apr 18, 2017

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Dec 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin. The primary hypothesis of this study is that after 52 weeks, the change from baseline in hemoglobin A1c (A1C) in participants treated with the addition of ertugliflozin 15 mg once daily is non-inferior compared with that in participants treated with the addition of glimepiride.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • Ertugliflozin 5 mgDrug

    Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104

  • Ertugliflozin 10 mgDrug

    Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.

  • GlimerpirideDrug

    Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose

  • Placebo to ErtugliflozinDrug

    Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104

  • Placebo to GlimepirideDrug

    Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.

  • MetforminDrug

    Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.

  • SitagliptinDrug

    Open label, oral, once daily, rescue medication as required.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue ApproachTime frame: Baseline and Week 52
  2. Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106Time frame: Up to Week 106
  3. Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104Time frame: Up to Week 104

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.